ASP-1929 (RM-1929)
Recurrent Head and Neck Squamous Cell Carcinoma (1L)
Phase 3Active
Key Facts
Indication
Recurrent Head and Neck Squamous Cell Carcinoma (1L)
Phase
Phase 3
Status
Active
Company
About Rakuten Medical
Rakuten Medical is a private, clinical-stage biotech pioneering the Alluminox™ platform, an investigational photoimmunotherapy designed for selective tumor cell killing. Its lead candidate, ASP-1929, is in a global Phase 3 trial for recurrent head and neck cancer, positioning the company in the late-stage oncology space. While its therapy is approved in Japan, Rakuten Medical is advancing global clinical development and has established key manufacturing and academic partnerships to support its mission of delivering innovative cancer treatments worldwide.
View full company profile